Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.851 | 0.160 | 16 | 56609431 | 3 prime UTR variant | G/C | snv | 0.26 |
|
Neoplasms | 0.020 | 1.000 | 2 | 2014 | 2015 | |||||||
|
16 | 56608372 | upstream gene variant | A/G | snv | 0.30 |
|
Neoplasms | 0.020 | 1.000 | 2 | 2014 | 2015 | |||||||||
|
0.763 | 0.240 | 16 | 56608579 | upstream gene variant | A/C;G | snv | 4.6E-02 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.020 | 1.000 | 2 | 2014 | 2017 | |||||||
|
0.763 | 0.240 | 16 | 56608579 | upstream gene variant | A/C;G | snv | 4.6E-02 |
|
Neoplasms; Male Urogenital Diseases | 0.020 | 1.000 | 2 | 2012 | 2013 | |||||||
|
0.763 | 0.240 | 16 | 56608579 | upstream gene variant | A/C;G | snv | 4.6E-02 |
|
Neoplasms; Male Urogenital Diseases | 0.020 | 1.000 | 2 | 2012 | 2013 | |||||||
|
0.763 | 0.240 | 16 | 56608579 | upstream gene variant | A/C;G | snv | 4.6E-02 |
|
Neoplasms | 0.020 | 1.000 | 2 | 2014 | 2015 | |||||||
|
0.763 | 0.240 | 16 | 56608579 | upstream gene variant | A/C;G | snv | 4.6E-02 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.020 | 1.000 | 2 | 2014 | 2017 | |||||||
|
0.851 | 0.160 | 16 | 56609431 | 3 prime UTR variant | G/C | snv | 0.26 |
|
Nutritional and Metabolic Diseases; Endocrine System Diseases | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||||
|
0.851 | 0.160 | 16 | 56609431 | 3 prime UTR variant | G/C | snv | 0.26 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
0.851 | 0.160 | 16 | 56609431 | 3 prime UTR variant | G/C | snv | 0.26 |
|
Nutritional and Metabolic Diseases; Endocrine System Diseases | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||||
|
0.851 | 0.160 | 16 | 56609431 | 3 prime UTR variant | G/C | snv | 0.26 |
|
Endocrine System Diseases | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||||
|
0.851 | 0.160 | 16 | 56609431 | 3 prime UTR variant | G/C | snv | 0.26 |
|
Nervous System Diseases | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||||
|
0.851 | 0.160 | 16 | 56609431 | 3 prime UTR variant | G/C | snv | 0.26 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
0.763 | 0.240 | 16 | 56608579 | upstream gene variant | A/C;G | snv | 4.6E-02 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||||
|
0.763 | 0.240 | 16 | 56608579 | upstream gene variant | A/C;G | snv | 4.6E-02 |
|
Eye Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
0.763 | 0.240 | 16 | 56608579 | upstream gene variant | A/C;G | snv | 4.6E-02 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||||
|
0.763 | 0.240 | 16 | 56608579 | upstream gene variant | A/C;G | snv | 4.6E-02 |
|
Neoplasms; Respiratory Tract Diseases; Otorhinolaryngologic Diseases | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.763 | 0.240 | 16 | 56608579 | upstream gene variant | A/C;G | snv | 4.6E-02 |
|
Neoplasms; Respiratory Tract Diseases; Otorhinolaryngologic Diseases | 0.010 | 1.000 | 1 | 2014 | 2014 |